Replies to post #203258 on Biotech Values

[ilpapa]

Thanks. Seems like they remain in a favorable place

[DewDiligence]

Additional granularity on 2Q16 Botox sales:

2Q16 Botox sales were 69% US, 31% ex-US.

Of the US sales, 61% were for medical indications and 39% for cosmetic indications.

The breakdown of ex-US sales was exactly reversed: 39% for medical indications and 61% for cosmetic indications.

Note: In all geographies, Botox's patient share in cosmetic indications in much greater than its dollar share in cosmetic indications—i.e. cosmetic indications use much less toxin per patient than medical indications.

[DewDiligence]

AGN’s 3Q16 Botox sales $690M, +14% YoY, -4% QoQ:

http://finance.yahoo.com/news/allergan-reports-third-quarter-2016-103500157.html

The QoQ decline is due to normal seasonality whereby cosmetic sales of Botox are higher in the second and fourth calendar quarters.